Featured Content
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Myeloma News
Phase 3 Trial of Ciltacabtagene Autoleucel Meets Primary Endpoint in Relapsed, Refractory Multiple Myeloma
Source: OncLive articles The trial is the first randomized phase 3 study evaluating the efficacy and safety of ciltacabtagene autoleucel patients with relapsed and lenalidomide-refractory multiple myeloma. Read More
GPRC5D as a novel immunotherapeutic target in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Efficacy and Safety of Ide-Cel Confirmed in Real-World Multiple Myeloma Population
Source: Myeloma - Hematology Advisor Researchers sought to confirm the safety and efficacy of idecabtagene vicleucel in a real-world population of patients with relapsed/refractory multiple myeloma. Read More
Unmet Needs in Treatment of Multiple Myeloma
Source: OncLive articles Kathryn Maples, PharmD, BCOP, provides insights regarding unmet needs in treatment for relapsed/refractory multiple myeloma. Read More
Treatment Landscape Surrounding Multiple Myeloma
Source: OncLive articles A panel of experts navigate the treatment landscape in multiple myeloma. Read More
Triplet Maintenance Extends PFS After Transplant in Multiple Myeloma
Source: Myeloma - Hematology Advisor Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma. Read More
Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
Source: Myeloma : nature.com subject feeds Post Content Read More
Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT
Source: Myeloma : nature.com subject feeds Post Content Read More
Multiple Myeloma Therapy Often Causes Cardiovascular Complications
Source: OncLive articles Many patients have baseline risk factors present at diagnosis because of older age and disease-related elements. Read More
Recent Publications
A Phase I Study of Selinexor Combined with Weekly Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Eur J Haematol. 2023 Feb 1. doi: 10.1111/ejh.13937. Online ahead of print. ABSTRACT We performed a phase I study of weekly selinexor, carfilzomib, and dexamethasone (wSKd) in patients with relapsed/refractory multiple myeloma (MM). The primary objective was to...
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
Cancer Med. 2023 Feb 1. doi: 10.1002/cam4.5584. Online ahead of print. ABSTRACT BACKGOUND: Lenalidomide-based regimens are commonly used for early relapse in patients with relapsed and/or refractory multiple myeloma (RRMM) receiving at least one prior line of therapy....
The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells
Front Immunol. 2023 Jan 16;13:1102471. doi: 10.3389/fimmu.2022.1102471. eCollection 2022. ABSTRACT Myeloid derived suppressors cells (MDSC) play major roles in regulating immune homeostasis and immune responses in many conditions, including cancer. MDSC interact with...
High-dose carfilzomib achieves superior anti-tumor activity over lowdose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex
Haematologica. 2023 Feb 2. doi: 10.3324/haematol.2022.282225. Online ahead of print. ABSTRACT The optimal carfilzomib dosing is a matter of debate. We analyzed the inhibition profiles of proteolytic proteasome subunits β5, β2 and β1 after low-dose (20/27 mg/m2) versus...
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial
Lancet Haematol. 2023 Feb;10(2):e107-e116. doi: 10.1016/S2352-3026(22)00372-6. ABSTRACT BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has shown activity in treating relapsed or refractory multiple myeloma;...
GPRC5D-targeting chimeric antigen receptors: a new treatment for multiple myeloma?
Lancet Haematol. 2023 Feb;10(2):e82-e83. doi: 10.1016/S2352-3026(22)00385-4. NO ABSTRACT PMID:36725123 | DOI:10.1016/S2352-3026(22)00385-4
GPRC5D as a novel immunotherapeutic target in multiple myeloma
Nat Rev Clin Oncol. 2023 Feb 1. doi: 10.1038/s41571-023-00735-4. Online ahead of print. NO ABSTRACT PMID:36725915 | DOI:10.1038/s41571-023-00735-4
A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy
Blood Adv. 2023 Feb 1:bloodadvances.2022008953. doi: 10.1182/bloodadvances.2022008953. Online ahead of print. NO ABSTRACT PMID:36724511 | DOI:10.1182/bloodadvances.2022008953
